He is one of the founders of ProQR, but even long before that Gerard Platenburg was involved in the development of RNA therapies. Even so, after decades of working on them he still gets enthusiastic when talking about RNA.
New therapies are thoroughly tested to ensure safety and efficacy, but for a company like ProQR, which aims to treat small groups of patients with rare diseases, innovating within the system is essential. Jessica is trying to rethink clinical trials.
There are currently around 160 people working at ProQR, but that wasn’t always the case. When Hee Lam Chan joined in 2013, she was only employee number six. As a result, she has seen the company grow and develop.
Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.
… her colleagues applied what she describes as “the amazing innovative retinal organoid model of ‘optic cups’.” She … and scientific chemistry”. Patricia insists that innovation can only be born in environments without …